MWNA
TEVA icon

Marshall Wace North America’s Teva Pharmaceuticals TEVA Stock Holding History

Marshall Wace North America’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-34,252
Closed -$528K – 1893
2018
Q4 		$528K Buy
+34,252
New +$702K 0.01% 765
2018
Q3 		– Sell
-449,276
Closed -$10.9M – 1360
2018
Q2 		$10.9M Buy
+449,276
New +$9.16M 0.06% 317
2013
Q3 		– Sell
-98,119
Closed -$3.85M – 705
2013
Q2 		$3.85M Buy
+98,119
New +$3.82M 0.3% 113

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace North America's TEVA Position: Q1 2019 in Review

Marshall Wace North America sold out of Teva Pharmaceuticals (TEVA) in Q1 2019, closing a stake of 34,252 shares — an estimated $528K sold.

Marshall Wace North America first reported a position in TEVA in Q2 2013 and held it in 3 quarters. The position peaked at $10.9M in Q2 2018. 521 funds tracked by Wall St. Rank hold TEVA as of Q1 2019.

  • Marshall Wace North America reported no remaining Teva Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Marshall Wace North America sold 34,252 Teva Pharmaceuticals shares in Q1 2019, an estimated $528K.
  • Marshall Wace North America first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • Marshall Wace North America's Teva Pharmaceuticals position peaked at $10.9M in Q2 2018.
  • 521 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2019.

Based on Marshall Wace North America's 13F filing for Q1 2019, filed 14 May 2019.